Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04295486

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For Venous Thromboembolism (VTE) Following Total Joint Arthroplasty - A Multi-center Prospective Randomized Control Trial.

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
5,478 (estimated)
Sponsor
University of Miami · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.

Conditions

Interventions

TypeNameDescription
DRUGAspirinNon-enteric coated 81 mg Aspirin tablet.

Timeline

Start date
2021-03-01
Primary completion
2027-03-01
Completion
2027-03-01
First posted
2020-03-04
Last updated
2026-03-11

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04295486. Inclusion in this directory is not an endorsement.

Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty (NCT04295486) · Clinical Trials Directory